Pharma Trends: Predictions for 2014-2015

by Jon Wetzel

To look forward we need to first look back.  From 2008-2012 we saw big pharma collide creating larger companies.  Genentech-Roche, Novartis-Alcon, Pfizer-Wyeth and GlaxoSmithKline-Human Genome Sciences just to name a few. 

During this same time frame the economies of the world have seen crashes and upheavals causing some of these same companies to “trim” their workforces.  What does all this mean for 2013-2015?

Economic worries will hold Operation Excellence in check for big pharma 2013-2015

I would love to say that all these companies are going to hire Lean and Six Sigma teams to help improve their efficiencies and decrease costs.  The reality is that I don’t see this happening.

With the economies of the world still not at a firm footing large pharmaceutical companies will continue to play it safe.  This means not investing heavily into departments that don’t have an immediate positive impact on their scientific or drug pipelines.

They will also still be wrestling with fusing their larger organizations together while deciding which divisions to either sell off or shut down.

Upside – Biotech will be ripe for OpEx

Either through acquisitions or strategic partnerships big pharma will be eyeing biotechs to help fill their drug pipeline.  Biotech companies are going to need to be lean and efficient if they hope to be considered a possible target by the larger pharma companies.

Smaller biotechs will be looking for outside consultants to help them clean up their operations.  Larger biotechs will look to bolster their existing programs or begin implementing new Operational Excellence Programs from the ground up.

A bumper crop of solid Biotechs 2013 – 2015

Emerging over the next 12-24 months will be biotech companies that are focused, efficient and “eye catching”.  They will be filled with innovative and forward thinking employees that are able to decrease costs while improving their organizations.

Expect 2014 and 2015 to be filled with larger pharmaceutical companies gobbling up these same biotechs and incorporating them into their larger organizations.

Change is in the air…and change is good if you’re a biotech company.

Fuente: Pharma IQ

Haciendo click en los links siguientes, accederán a los Contenidos de algunos de nuestros CURSOS A MEDIDA:

Programa Ejecutivo en PENSAMIENTO ESTRATÉGICO

http://msg-latam-meic.blogspot.com.ar/2014/04/programa-ejecutivo-en-pensamiento.html

Programa Ejecutivo en MANAGEMENT ESTRATÉGICO

http://msg-latam-meic.blogspot.com.ar/2014/04/programa-ejecutivo-en-management.html

Programa Ejecutivo en GESTIÓN DEL CAMBIO

http://msg-latam-meic.blogspot.com.ar/2014/04/programa-ejecutivo-en-gestion-del.html

Taller de ESTRATEGIAS EFECTIVAS para ESCENARIOS TURBULENTOS

http://msg-latam-meic.blogspot.com.ar/2014/04/taller-de-estrategias-efectivas-para.html

Por dictado IN COMPANY, consultar al mail: msg.latam@gmail.com

ó al +5411-3532-0510